Workstream Type: Policy Comments
Formal responses to government RFIs
-
Medicare Part B Premium Dynamics Explained
-
Comparing Factors that Influence Pharmaceutical Pricing and Access in the US and five other Countries
-
Biosimilars in Medicare Part D: pricing dynamics and considerations
-
What A Waste! The National Academy Of Medicine’s Report On Oversized Vials Of Expensive Drugs
-
Trump’s Drug-Pricing Ideas Would Cost Taxpayers a Bundle
-
After 4 Years of Trump, Medicare and Medicaid Badly Need Attention
-
CMS’s Proposed Medicaid Best Price Loophole for Value-Based Purchasing of Drugs
-
CMS Announces Delay of MCIT Final Rule
-
Research on the current state of US drug pricing and its effects
-
Who Is Sowing Seeds of Confusion About The QALY?